LB PHARMACEUTICALS INC
Business
LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel antipsychotic and neuropsychiatric therapies. The company's lead product candidate, LB-102, is a patented benzamide derivative designed to improve upon amisulpride, currently in Phase 3 clinical trials for schizophrenia with planned Phase 2 trials in bipolar depression and adjunctive major depressive disorder. LB-102 is being developed for U.S. and international markets, with the company retaining commercialization rights in the U.S. and evaluating partnerships outside the U.S.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Research and development | 17 | 51 | |
| General and administrative | 14 | 14 | |
| Total operating loss | −30 | −65 | |
| Interest income | 4 | 2 | |
| Realized gain on sale of marketable securities, net | 119,000 | 955,000 | |
| Gain (loss) on change in fair value of derivative instruments | 1 | −947,000 | |
| Total non-operating income | 5 | 2 | |
| Loss before income tax | −25 | −63 | |
| Income tax provision | 1,000 | 1,000 | |
| Net loss | −25 | −63 | |
| Net loss per share, basic | −3.13 | −176.15 | |
| Net loss per share, diluted | −3.13 | −176.15 | |
| Weighted average shares outstanding used in calculating net loss per share, basic | 8 | 358,229 | |
| Weighted average shares outstanding used in calculating net loss per share, diluted | 8 | 358,229 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-09-30 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 250 | — | 23 | — | |
| Marketable securities | 45 | — | 5 | — | |
| Prepaid expenses and other current assets | 13 | — | 880,000 | — | |
| Total current assets | 308 | — | 29 | — | |
| Operating lease right-of-use assets, net | 2 | — | 2 | — | |
| Property and equipment, net | 2 | — | 2 | — | |
| Restricted cash | 770,000 | — | 498,000 | — | |
| Total assets | 313 | — | 34 | — | |
| Accounts payable | 2 | — | 2 | — | |
| Accrued expenses | 5 | — | 5 | — | |
| Operating lease liability, current | 730,000 | — | 487,000 | — | |
| Total current liabilities | 7 | — | 8 | — | |
| Derivative liability - warrants | 1 | — | 3 | — | |
| Operating lease liability, noncurrent | 3 | — | 3 | — | |
| Total liabilities | 12 | — | 14 | — | |
| Commitments and contingencies (Note 13) | — | — | — | — | |
| Common stock, $0.0001 par value, 500,000,000 and 105,000,000 shares authorized, 25,299,372 and 251,655 shares issued and outstanding as of December 31, 2025 and 2024, respectively. | 3,000 | 114 | 1,000 | — | |
| Additional paid-in capital | 431 | — | 10 | — | |
| Accumulated deficit | −130 | — | −104 | — | |
| Accumulated other comprehensive income | 168,000 | — | 111,000 | — | |
| Total stockholders' equity (deficit) | 301 | — | −95 | −34 | |
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | 313 | — | 34 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Stock-based compensation expense | 4 | 3 | |
| Shares issued for services rendered | 0 | 71,000 | |
| Loss on write off of property and equipment | 8,000 | 0 | |
| Write off of deferred offering costs | 0 | 3 | |
| Depreciation and amortization | 321,000 | 91,000 | |
| Noncash lease expense | 147,000 | 308,000 | |
| Realized gain on sale of marketable securities, net | −119,000 | −955,000 | |
| Amortization (accretion) of premiums (discounts) on investments, net | 261,000 | −34,000 | |
| (Gain) loss on change in fair value of derivative instruments | −1 | 947,000 | |
| Prepaid expenses and other current assets | −12 | −2 | |
| Operating lease liability | −134,000 | −60,000 | |
| Accrued interest on marketable securities | −268,000 | 114,000 | |
| Accounts payable and accrued expenses | −910,000 | 5 | |
| Net cash used in operating activities | −35 | −53 | |
| Purchases of property and equipment | −52,000 | −769,000 | |
| Purchase of marketable securities | −45 | −30 | |
| Proceeds from the sale of marketable securities | 3 | 24 | |
| Maturities of marketable securities | 3 | 30 | |
| Net cash (used in) provided by investing activities | −40 | 23 | |
| Proceeds from initial public offering | 328 | 0 | |
| Payment of issuance costs for initial public offering | −25 | 0 | |
| Proceeds from exercise of warrants and options | 247,000 | 23,000 | |
| Proceeds from issuance of redeemable convertible Series C preferred stock | 0 | 40 | |
| Payment of issuance costs for redeemable convertible Series C preferred stock | 0 | −2 | |
| Net cash provided by financing activities | 303 | 38 | |
| Net increase in cash, cash equivalents and restricted cash | 227 | 8 | |
| Income tax paid | 1,000 | 1,000 | |
| Conversion of 78,072,306 shares (1) of redeemable convertible preferred stock to common stock upon the closing of initial public offering | 114 | 0 | |
| Right of use assets in exchange for operating lease liabilities | 0 | 2 | |
| Acquisition of leasehold improvements | 0 | 1 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is LB PHARMACEUTICALS INC's CIK number?
LB PHARMACEUTICALS INC's SEC CIK number is 0001691082 (1691082). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find LB PHARMACEUTICALS INC's SEC filings?
All of LB PHARMACEUTICALS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did LB PHARMACEUTICALS INC last report earnings?
LB PHARMACEUTICALS INC (LBRX) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-219529). This is LB PHARMACEUTICALS INC's most recent earnings filing of record — not a forecast of its next earnings date.
What is LB PHARMACEUTICALS INC's most recent earnings 8-K?
LB PHARMACEUTICALS INC's latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-219529. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View LB PHARMACEUTICALS INC's latest earnings 8-K →
Look up any company's CIK number →